Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple-negative breast cancer, while ongoing clinical trial...
As treatment options for metastatic breast cancer expand and as quality of life and overall survival improve, researchers are targeting potential treatments for this sanctuary site. Attention is now being focused on defining the phenotype of breast cancer that has a propensity to metastasize to the ...
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple-negative breast cancer, while ongoing clinical trial...
treatment for HER-2-positive breast cancer in Western countries. In Japan, trastuzumab was approved for the indication of metastatic breast cancer with HER-2 overexpression in 2001. In 2008, trastuzumab was approved as postoperative adjuvant chemotherapy for breast cancer with confirmed HER-2 ...
As for postoperative adjuvant chemotherapy, an anthracycline plus cyclophosphamide and taxane-based regimens are standard treatments in Japan and Western countries. In 2009, however, the results of two large clinical studies designed to determine whether intravenous or oral treatment was superior for ...
Future research on treatments for patients with HER2+ breast cancer is focusing on developing novel drugs that can specifically target cancer cells with minimal side effects as well as on the implementation of novel technologies, such as artificial intelligence for integrating clinical and genomic data...
These results suggest that the increased sensitivity to radiotherapy observed with TTFields could be mediated through both an increase in DNA damage and reduced repair capacity following TTFields treatments.53 Consistent with these findings, differential gene expression analysis revealed that the expression ...
Current status of endocrine therapy for breast cancer Adjuvant endocrine therapy is a vitally important modality for treatment of women with resected hormone-sensitive breast cancer as indicated by the presenc... 三好,康雄,野口,眞三郎 - 《外科治療》 被引量: 1发表: 2007年 Current status of endo...
Breast cancer metastasizing to the central nervous system (CNS) encompasses two distinct entities: brain metastases involving the cerebral parenchyma and i
Targeted therapy and immunotherapy are emerging as standard treatment options for a significant subset of patients with breast cancer. However, the safety of specific treatments and the timing of treatment are unique in those patients who are pregnant when diagnosed with breast cancer. Summary The inc...